Health
Johnson & Johnson’s Coronavirus Vaccine Candidate Efficacious in Pre-Clinical Studies; Human Testing Has Begun – The Motley Fool
The company aims to start a phase 3 clinical trial for Ad26.COV2-S in September.
Johnson & Johnson(NYSE:JNJ) has gained some ground in the coronavirus vaccine race. On Thursday, the pharmaceutical and consumer goods company announced that in pre-clinical studies, its Ad26.COV2-S vaccine candidate had demonstrated effectiveness in protecting on non-human primates from infection with SARS-CoV-2.
In contrast to other coronavirus vaccine candidates — such as the one many observers view as the most promising, Moderna’s mRNA-1273 — Johnson & Johnson’s produced its respo…
-
Noosa News21 hours agoDog daycare program a TikTok hit for helping disabled find work, friends
-
Noosa News23 hours agoParkyn this, Parkyn that | Noosa Today
-
Noosa News23 hours agoR Tee in the running to be top dog
-
Noosa News21 hours agoAdvocates highlight sexual violence against older people, with Queensland elder abuse inquiry underway